Novo Nordisk Finds Relief as Rival's Production Woes and Buyback Bolster Recovery

Novo Nordisk shares rebound 43% from March lows, supported by a $2.2B buyback program and a manufacturing setback at generics rival Dr. Reddy’s, which halts semaglutide output until 2026.

Novo Nordisk shares have climbed more than 43% from their March nadir, riding a recovery that now draws support from two distinct forces: a massive share repurchase programme and a manufacturing stumble at a key generics rival. The Danish drugmaker closed Friday at €43.32 in European trading, up 1.29% on the day, though the stock remains 29% below its 52-week peak of €61.20 set last July.

Generics Competitor Halts Semaglutide Output

Dr. Reddy's Laboratories disclosed on Thursday that certain batches of its semaglutide active ingredient failed to meet specifications, forcing it to halt deliveries of its copycat diabetes and weight-loss injection. The Indian generics manufacturer now expects normal supply to resume no earlier than October 2026, as validation procedures will take considerable time. The disruption has cascaded to partners Torrent Pharmaceuticals and USV Ltd, which source semaglutide from Dr. Reddy's and have initiated precautionary recalls of select batches.

For Dr. Reddy's, the setback carries a heavy cost: the company slashed its annual volume forecast by 45% to 50%. The incident underscores the complexity of manufacturing injectable semaglutide at scale — a barrier that has kept Novo Nordisk's patent-protected franchise largely insulated from generic incursion even as half a dozen Indian producers launch cheaper copies. While the stoppage offers Novo Nordisk a temporary respite, it also hands an edge to competing generics players such as Sun Pharma and Zydus. Notably, Dr. Reddy's semaglutide tablets are unaffected, as they come from a different active-ingredient source.

Buyback Programme Provides Technical Support

Alongside the competitive tailwind, Novo Nordisk's own share repurchase plan is underpinning the stock. Under a programme running from February 4, 2026, for up to 12 months, the company intends to buy back B-shares worth up to 15 billion Danish kroner. As of July 3, it had purchased roughly 23 million B-shares at an average price of 270.32 kroner apiece, spending about 6.2 billion kroner in total. Novo Nordisk now holds 40,194,480 of its own B-shares, equivalent to 0.9% of total capital across A and B classes.

The near-daily buybacks are viewed by market participants as an important technical prop at a time when pricing pressure in the obesity market is intensifying — particularly from Eli Lilly's Tirzepatide-based Zepbound and Mounjaro franchise.

Analyst Views Remain Split

Sentiment among analysts is stabilising after months of downgrades, but opinions diverge on how much of the recent rally is driven by genuine fundamental improvement versus short-covering and buyback-induced demand. HSBC raised its price target on Novo Nordisk in early July to 300 Danish kroner from 280, while Nordea upgraded the stock from Hold to Buy in June. J.P. Morgan and Deutsche Bank, however, maintain their Hold ratings, reflecting lingering caution.

Pipeline Developments and the Next Catalyst

Investors are also watching Novo Nordisk's pipeline for obesity treatments. A phase 2 study comparing two injector versions of CagriSema was marked as withdrawn on ClinicalTrials.gov in early July. Meanwhile, early-stage work continues, including a dose-escalation trial for an experimental obesity compound. The broader metabolic pipeline remains active.

The stock's technical position shows it trading above both its 50-day moving average of €39.51 and its 200-day line of €40.60. The 14-day relative strength index stands at 66 — elevated but not yet in overbought territory — while annualised volatility of roughly 30% signals the shares remain sensitive to competitive and regulatory newsflow.

The next major inflection point comes in August with the release of half-year results. Investors will be looking for updated guidance on obesity-product sales, details on Wegovy tablet uptake in the US, and management's latest assessment of the competitive landscape against Eli Lilly. Until then, the daily rhythm of buybacks and the lingering impact of Dr. Reddy's production halt should keep Novo Nordisk's shares in a support zone, even as the broader recovery still has ground to cover to reclaim its former highs.